Relationship between Cyclooxygenase-2 Inhibition and Thrombogenesis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue 1, 2004, Pages 51-59

  Dai, Wangde ^a   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cyclooxygenase 2; Myocardial infarction; Thrombogenesis

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL INTERACTION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; REVIEW; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 1942510391     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900i108     Document Type: Review

References (61)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 343:1520-1528, 2000
2. Anggard E, Samuelsson B. Biosynthesis of prostaglandins from arachidonic acid in guinea pig lung. Prostaglandins and related factors. J Biol Chem 240:3518-3521, 1965
3. Hemler M, Lands WEM, Smith WL. Purification of the cyclooxygenase that forms prostaglandins; demonstration of the two forms of iron in the holoenzyme. J Biol Chem 251:5575-5579, 1976
4. Funk CD. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294 (30):1871-1875, 2001
5. Vane JR. Back to an aspirin a day? Science 296:474-475, 2002
6. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 12:1063-1073, 1998
7. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 89:650-660, 2001
8. Lipsky PE. The clinical potential of cyclooxygenase-2-specific inhibitors. Am J Med 106(5B):51s-57s, 1999
9. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96(1):272-277, 1999
10. DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 89(6A):33D-38D, 2002
11. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 106(5B):37s-42s, 1999
12. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 89:650-660, 2001
13. Weber AA, Przytulski B, Schumacher M, et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: Induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 117(2):424-426, 2002
14. Reiter R, Resch U, Sinzinger H. Do human platelets express COX-2? Prostaglandins Leukot Essent Fatty Acids 64(6):299-305, 2001
15. Patrignani P, Sciulli MG, Manarini S, et al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 50(4):661-667, 1999
16. Selwyn AP. Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol 91(suppl): 3H-11H, 2003
17. Reilly M, Fitzgerald GA. Cellular activation by thromboxane A2 and other eicosanoids. Eur Heart J 14(suppl K):88-93, 1993
18. Folts JD, Schafer AI, Loscalzo J, et al. A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 33:295-303, 1999
19. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 40(2):124-132, 2000
20. Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J Mol Cell Cardiol 31:23-37, 1999
21. Skidgel RA, Printz MP. PGI2 production by rat blood vessels: Diminished prostacyclin formation in veins compared arteries. Prostaglandins 16:1-16, 1978
22. Salmon JA, Smith DR, Flower RJ, et al. Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta 523:250-262, 1978
23. Werns SW, Walton JA, Hsia HH, et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 79:287-291, 1989
24. Anderson TJ, Gerhard MD, Meredith IT, et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 75:71B-74B, 1995
25. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J 18 (Suppl E):E19-E29, 1997
26. 2-mediated mechanism of vascular contraction in hypertensive rats, relation to lipoxygenase and prostacyclin synthase activities. Circ Res 74:197-205, 1994
27. Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 97:716-720, 1998
28. Bustos M, Coffman TM, Saadi S, et al. Modulaion of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. J Clin Invest 100(5):1150-1168, 1997
29. Verma S, Raj SR, Shewchuk L, et al. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 104(24):2879-2882, 2001
30. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42(3):310-315, 2003
31. Catella-lawson F. Vascular biology of thrombosis: Platelet-vessel wall interactions and aspirin effects. Neurology 57(5 suppl 2):s5-s7, 2001
32. Marcus AJ, Broekman MJ, Pinsky DJ. COX Inhibitors and thromboregulation. N Engl J Med 347(13):1025-1026, 2002
33. Bunting S, Moncada S, Vane JR. The prostacyclin-thromboxane A2 balance: Pathophysiological and therapeutic implications. Br Med Bull 39(3):271-276, 1983
34. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 6(5B):25s-36s, 1999
35. Caughey GE, Cleland LG, Gamble JR, et al. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem 276(41):37839-37845, 2001
36. Dogne JM, de Leval X, Delarge J, et al. New trends in thromboxane and prostacyclin modulartors. Curr Med Chem 7(6):609-628, 2000
37. Moncada S, Vane VR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 30:293-331, 1979
38. FitzGerald GA, Smith B, Pedersen AK, et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 310(17):1065-1068, 1984
39. Pitt B, Shea MJ, Romson JL, et al. Prostaglandins and prostaglandin inhibitors in ischemic heart disease. Ann Intern Med 99:83-92, 1983
40. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: Clinical consideration. Am J Cardiol 89(6A):26D-32D, 2002
41. Hennan JK, Huang J, Barrett TD, et al, Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104(7):820-825, 2001
42. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: Mechanisms and clinical therapeutic approaches. Vasc Med 3(3):231-239, 1998
43. Robbie L, Libby P. Inflammation and atherothrombosis. Ann N Y Acad Sci 947:167-179, 2001
44. Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am J Med 113:668-680, 2002
45. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart 87:201-204, 2002
46. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155:1281-1291, 1999
47. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 19:646-655, 1999
48. Altman R, Scazziota A. Role of anti-inflammatory drugs in the treatment of acute coronary syndromes. From athero-inflammation to athero-thrombosis. Rev Esp Cardiol 56(1):9-15, 2003
49. Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 106(2):191-195, 2002
50. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The Celecoxib Long-term Arthritis Safety Study (CLASS): A randomized controlled trial. JAMA 284:1247-1255, 2000
51. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959, 2001
52. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 162:1099-1104, 2002
53. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 359:118-123, 2002
54. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 106:167-169, 2002
55. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2 specific inhibitors and cardiorenal function: A randomized controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8:85-95, 2001
56. Reicin AS, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 89(2):204-209, 2002
57. Barnnwarth B, Treves R, Euller-Ziegler L, et al. Adverse events associated with rofecoxib therapy: Results of a large study in community-derived osteoarthritic patients. Drug Saf 26(1):49-54, 2003
58. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9): 1303-1307, 2003
59. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30(6):1196-1202, 2003
60. Solomon DH, Avorn J. Pharmacoepidemiology and rheumatic diseases: 2001-2002. Curr Opin Rheumatol 15(2):122-126, 2003
61. Hochberg MC. COX-2: Where are we in 2003?-Be strong and resolute: Continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. Arthritis Res Ther 5(1):28-31, 2003